Table 1 Demographics and characteristics for retreatment baseline
From: Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
Characteristic | HL patients | ALCL patients |
|---|---|---|
(N = 21) | (N = 8) | |
Age, year | ||
Median (range) | 30 (16, 65) | 51.5 (24, 72) |
Gender, no. (%) | ||
Male | 10 (48) | 4 (50) |
Female | 11 (52) | 4 (50) |
Race, no. (%) | ||
Other | 0 (0) | 1 (13) |
Black or African American | 2 (10) | 2 (25) |
White | 19 (90) | 5 (63) |
ECOG Performance Status, no. (%) | ||
0 | 8 (38) | 3 (38) |
1 | 12 (57) | 4 (50) |
2 | 1 (5) | 1 (13) |
Initial diagnosis, no. (%) | ||
ALK positive | -- | 3 (38) |
ALK negative | -- | 5 (63) |
Number of prior systemic therapiesa | ||
Median (range) | 4 (2, 12) | 3 (2, 6) |
Time between last brentuximab vedotin dose on prior study and first dose of retreatment (months) | ||
Median (range) | 11.4 (4, 45) | 4.7 (2, 15) |
Number of patients with intervening systemic therapies, n (%) | 6 (21) | 0 |
Best response, n/n (%) | ||
Stable disease | 1 (17) | -- |
Progressive disease | 4 (67) | -- |
Unknown/other | 1 (17) | -- |
Disease status relative to most recent prior therapy, n (%) | ||
Refractory | 5 (24) | 0 |
Relapse after response | 16 (76) | 8 (100) |